AMRI Announces the Promotion of Richard Saffee
News Jan 09, 2013
AMRI has announced that Richard A. Saffee has been promoted to the newly created role of Vice President and General Manager of Large Scale Manufacturing, effective immediately.
He will continue to report to Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing.
Mr. Saffee will assume oversight for large scale manufacturing in Aurangabad, India in addition to his current responsibilities for leadership of AMRI’s large scale manufacturing and GMP business in the United States in the Capital Region of New York.
Additionally, Mr. Saffee will work with AMRI’s Holywell, UK site to assist them in their large scale manufacturing business.
Mr. Saffee will be positioned to drive synergies between the locations that will improve quality, efficiency and delivery of world class API’s.
“We are pleased to announce this promotion of Mr. Saffee,” said Dr. Hagen. “Mr. Saffee joined AMRI in 2009 with more than 23 years of industrial and leadership experience in the chemical manufacturing of bulk Active Pharmaceutical Ingredients (API) for both human and animal health. Since joining AMRI, Rick’s leadership has been instrumental in many successes achieved at the Rensselaer large scale manufacturing location. We look forward to his leadership in our continued efforts to achieve closer integration among all of our manufacturing facilities.”
Backed by an excellent compliance history and track record, AMRI’s worldwide manufacturing facilities are equipped for Phase I through commercial API manufacturing.
As a part of AMRI’s SMARTSOURCING™ initiative, this closer integration of facilities under Mr. Saffee provides an added advantage as customers move their compounds from early development to high potency and large scale manufacturing.
These global sites in the United States, Europe and Asia also provide tailored solutions for the biotech and pharma industry, and enable the efficient, cost-effective transfer of products and projects.
AMRI also provides raw materials and starting materials for cGMP manufacturing of API.
Before coming to AMRI, Mr. Saffee led manufacturing activities for multiple U.S.-based operations for Pfizer Global Manufacturing. and Pfizer Global Human Health.
Prior to the acquisition of Parke-Davis by Pfizer, Mr. Saffee held roles of increasing responsibility at Parke-Davis including Director of Chemical Manufacturing and Area Production Manager.
He has extensive knowledge in the areas of chemical manufacturing, technology transfer, regulatory compliance and quality standards, purchasing and materials management and managing global relationships. He is also trained in Lean Six Sigma techniques.
Mr. Saffee earned a Master’s degree in Business Administration from Grand Valley State University in Allendale, Michigan and a Bachelor’s of Science degree in Chemical Engineering from the University of Michigan in Ann Arbor, Michigan.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE